Trust 1 four operators | Trust 2 four operators 2017 five operators 2018 | Trust 3 one operator 2017 two operators 2018 | Trust 4 seven operators | Trust 5 two operators | ||||||
2017 | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | |
Number of diagnostic EBUS | 98 | 122 | 26 | 24 | 118 | 27 | 54 | 81 | 19 | 21 |
Pathological diagnosis | 91% | 96% | 80% | 91% | 98% | 93% | 93% | 91% | 94% | 95% |
NSCLC-NOS rate | 3% (4/154) | 4% (7/193) | 25% (11/44) | 21% (8/39) | 2% (4/214) | 35% (68/197) | 7% (8/113) | 8% (8/98) | 17% 5/29 | 15% 4/27 |
Adequate tissue for EGFR | 91% (89/98) | 96% (117/122) | 55% (12/22) | 57% (8/14) | 99% (93/94) | 90% (63/70) | 90% (55/61) | 90% 35/39) | 87% 13/15 | 94% 17/18 |
Adequate tissue for ALK | 98% (96/98) | 97% (89/92) | 64% (16/22) | 50% (6/12) | 100% (30/30) | 90% (62/69) | 90% (51/57) | 93% 37/40 | 80% 12/15 | 89% 16/18 |
EBUS, endobronchial ultrasound; EGFR, epidermal growth factor receptor; NOS, not otherwise specified; NSCLC, nonsmall cell lung cancer.